Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 730

1.

Structural and functional footprint of visual snow syndrome.

Schankin CJ, Maniyar FH, Chou DE, Eller M, Sprenger T, Goadsby PJ.

Brain. 2020 Mar 24. pii: awaa053. doi: 10.1093/brain/awaa053. [Epub ahead of print]

PMID:
32211752
2.

Evolving options for the treatment of cluster headache.

Villar-Martinez MD, Chan C, Goadsby PJ.

Curr Opin Neurol. 2020 Mar 23. doi: 10.1097/WCO.0000000000000808. [Epub ahead of print]

PMID:
32209808
3.

Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2.

Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, Pederson S, Allan B, Cady R.

Neurology. 2020 Mar 24. pii: 10.1212/WNL.0000000000009169. doi: 10.1212/WNL.0000000000009169. [Epub ahead of print]

PMID:
32209650
4.

Headache and non-headache symptoms provoked by nitroglycerin in migraineurs: A human pharmacological triggering study.

Karsan N, Bose PR, Thompson C, Newman J, Goadsby PJ.

Cephalalgia. 2020 Mar 12:333102420910114. doi: 10.1177/0333102420910114. [Epub ahead of print]

PMID:
32164428
5.

Insular and occipital changes in visual snow syndrome: a BOLD fMRI and MRS study.

Puledda F, Ffytche D, Lythgoe DJ, O'Daly O, Schankin C, Williams SCR, Goadsby PJ.

Ann Clin Transl Neurol. 2020 Mar;7(3):296-306. doi: 10.1002/acn3.50986. Epub 2020 Mar 10.

6.

PAC1 receptor blockade reduces central nociceptive activity: new approach for primary headache?

Hoffmann J, Miller S, Martins-Oliveira M, Akerman S, Supronsinchai W, Sun H, Shi L, Wang J, Zhu D, Lehto S, Liu H, Yin R, Moyer BD, Xu C, Goadsby PJ.

Pain. 2020 Mar 4. doi: 10.1097/j.pain.0000000000001858. [Epub ahead of print]

PMID:
32142016
7.

The need for continued care after sponsor closure - Authors' reply.

Goadsby PJ, Rezai AR, Dodick DW.

Lancet Neurol. 2020 Mar;19(3):205-206. doi: 10.1016/S1474-4422(20)30024-7. No abstract available.

PMID:
32085831
8.

Response to 'Do different treatment strategies of galcanezumab have similar effect on migraine?'

Goadsby PJ, Terwindt GM, Ruff DD, Ford JH, Tockhorn-Heidenreich A, Stauffer VL, Govindan S, Aurora SK.

Eur J Neurol. 2020 Feb 12. doi: 10.1111/ene.14168. [Epub ahead of print] No abstract available.

PMID:
32052515
9.

Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment.

Dodick DW, Goadsby PJ, Lucas C, Jensen R, Bardos JN, Martinez JM, Zhou C, Aurora SK, Yang JY, Conley RR, Oakes T.

Cephalalgia. 2020 Feb 12:333102420905321. doi: 10.1177/0333102420905321. [Epub ahead of print]

PMID:
32050782
10.

Acid-sensing ion channel 3 blockade inhibits durovascular and nitric oxide-mediated trigeminal pain.

Holton CM, Strother LC, Dripps I, Pradhan AA, Goadsby PJ, Holland PR.

Br J Pharmacol. 2020 Jan 23. doi: 10.1111/bph.14990. [Epub ahead of print]

PMID:
31975427
11.

Visual snow syndrome: A clinical and phenotypical description of 1,100 cases.

Puledda F, Schankin C, Goadsby PJ.

Neurology. 2020 Feb 11;94(6):e564-e574. doi: 10.1212/WNL.0000000000008909. Epub 2020 Jan 15.

PMID:
31941797
12.

Imaging the Visual Network in the Migraine Spectrum.

Puledda F, Ffytche D, O'Daly O, Goadsby PJ.

Front Neurol. 2019 Dec 13;10:1325. doi: 10.3389/fneur.2019.01325. eCollection 2019. Review.

13.

Migraine: a brain state amenable to therapy.

Eller M, Goadsby PJ.

Med J Aust. 2020 Jan;212(1):32-39. doi: 10.5694/mja2.50435. Epub 2019 Dec 6. Review.

PMID:
31808561
14.

Biochemical Modulation and Pathophysiology of Migraine.

Chan C, Wei DY, Goadsby PJ.

J Neuroophthalmol. 2019 Dec;39(4):470-479. doi: 10.1097/WNO.0000000000000875.

PMID:
31714319
15.

Safety and efficacy of sphenopalatine ganglion stimulation for chronic cluster headache: a double-blind, randomised controlled trial.

Goadsby PJ, Sahai-Srivastava S, Kezirian EJ, Calhoun AH, Matthews DC, McAllister PJ, Costantino PD, Friedman DI, Zuniga JR, Mechtler LL, Popat SR, Rezai AR, Dodick DW.

Lancet Neurol. 2019 Dec;18(12):1081-1090. doi: 10.1016/S1474-4422(19)30322-9.

PMID:
31701891
16.

Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials.

Ruff DD, Ford JH, Tockhorn-Heidenreich A, Stauffer VL, Govindan S, Aurora SK, Terwindt GM, Goadsby PJ.

Eur J Neurol. 2020 Apr;27(4):609-618. doi: 10.1111/ene.14114. Epub 2019 Dec 2.

PMID:
31692188
17.

Migraine progression in subgroups of migraine based on comorbidities: Results of the CaMEO Study.

Lipton RB, Fanning KM, Buse DC, Martin VT, Hohaia LB, Adams AM, Reed ML, Goadsby PJ.

Neurology. 2019 Dec 10;93(24):e2224-e2236. doi: 10.1212/WNL.0000000000008589. Epub 2019 Nov 5.

18.

An Update: Pathophysiology of Migraine.

Goadsby PJ, Holland PR.

Neurol Clin. 2019 Nov;37(4):651-671. doi: 10.1016/j.ncl.2019.07.008. Review.

PMID:
31563225
19.

Recent Advances in Pharmacotherapy for Episodic Migraine.

Chan C, Goadsby PJ.

CNS Drugs. 2019 Nov;33(11):1053-1071. doi: 10.1007/s40263-019-00665-9.

PMID:
31556018
20.

Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults.

Goadsby PJ, Tepper SJ, Watkins PB, Ayele G, Miceli R, Butler M, Severt L, Finnegan M, Szegedi A, Trugman JM, Jakate A.

Cephalalgia. 2019 Dec;39(14):1753-1761. doi: 10.1177/0333102419869918. Epub 2019 Sep 19.

21.

Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-controlled PREMIUM trial.

Diener HC, Goadsby PJ, Ashina M, Al-Karagholi MA, Sinclair A, Mitsikostas D, Magis D, Pozo-Rosich P, Irimia Sieira P, Làinez MJ, Gaul C, Silver N, Hoffmann J, Marin J, Liebler E, Ferrari MD.

Cephalalgia. 2019 Oct;39(12):1475-1487. doi: 10.1177/0333102419876920. Epub 2019 Sep 15.

22.

Aura and Head pain: relationship and gaps in the translational models.

Bolay H, Vuralli D, Goadsby PJ.

J Headache Pain. 2019 Sep 3;20(1):94. doi: 10.1186/s10194-019-1042-8. Review.

23.

Primary headache disorders: Five new things.

Goadsby PJ.

Neurol Clin Pract. 2019 Jun;9(3):233-240. doi: 10.1212/CPJ.0000000000000654.

24.

Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.

Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, Coric V, Lipton RB.

Lancet. 2019 Aug 31;394(10200):737-745. doi: 10.1016/S0140-6736(19)31606-X. Epub 2019 Jul 13.

PMID:
31311674
25.

Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine.

Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, Dubowchik GM, Conway CM, Coric V, Goadsby PJ.

N Engl J Med. 2019 Jul 11;381(2):142-149. doi: 10.1056/NEJMoa1811090.

PMID:
31291516
26.

Trial of Galcanezumab in Prevention of Episodic Cluster Headache.

Goadsby PJ, Dodick DW, Leone M, Bardos JN, Oakes TM, Millen BA, Zhou C, Dowsett SA, Aurora SK, Ahn AH, Yang JY, Conley RR, Martinez JM.

N Engl J Med. 2019 Jul 11;381(2):132-141. doi: 10.1056/NEJMoa1813440.

PMID:
31291515
27.

Targeting CGRP and 5-HT1F Receptors for the Acute Therapy of Migraine: A Literature Review.

Moreno-Ajona D, Chan C, Villar-Martínez MD, Goadsby PJ.

Headache. 2019 Jul;59 Suppl 2:3-19. doi: 10.1111/head.13582. Review.

PMID:
31291016
28.

Managing cluster headache.

Wei DY, Khalil M, Goadsby PJ.

Pract Neurol. 2019 Dec;19(6):521-528. doi: 10.1136/practneurol-2018-002124. Epub 2019 Jul 5.

29.

Differential efficacy of non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A meta-analysis.

de Coo IF, Marin JC, Silberstein SD, Friedman DI, Gaul C, McClure CK, Tyagi A, Liebler E, Tepper SJ, Ferrari MD, Goadsby PJ.

Cephalalgia. 2019 Jul;39(8):967-977. doi: 10.1177/0333102419856607. Epub 2019 Jun 10.

30.

Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial.

Dodick DW, Lipton RB, Silberstein S, Goadsby PJ, Biondi D, Hirman J, Cady R, Smith J.

Cephalalgia. 2019 Aug;39(9):1075-1085. doi: 10.1177/0333102419858355. Epub 2019 Jun 24.

PMID:
31234642
31.

The Association Between Parental Migraine and Infant Colic: A Cross-Sectional, Web-Based, U.S. Survey Study.

Gelfand AA, Buse DC, Cabana MD, Grimes B, Goadsby PJ, Allen IE.

Headache. 2019 Jul;59(7):988-1001. doi: 10.1111/head.13575. Epub 2019 Jun 20.

PMID:
31222745
32.

Cluster Headache in Kuwait: A Hospital-Based Study.

Al-Hashel J, Ibrahim I, Youssry D, Ahmed SF, Goadsby P.

Front Neurol. 2019 Jun 4;10:573. doi: 10.3389/fneur.2019.00573. eCollection 2019.

33.

Trigeminal autonomic cephalalgias presenting in a multidisciplinary tertiary orofacial pain clinic.

Wei DY, Moreno-Ajona D, Renton T, Goadsby PJ.

J Headache Pain. 2019 Jun 11;20(1):69. doi: 10.1186/s10194-019-1019-7.

34.

Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine.

Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick D, Rippon GA, Klatt J, Xue F, Chia V, Zhang F, Cheng S, Mikol DD.

Cephalalgia. 2019 Oct;39(11):1455-1464. doi: 10.1177/0333102419854082. Epub 2019 May 30.

35.

James W. Lance MD.

Goadsby PJ.

Headache. 2019 Jun;59(6):825-827. doi: 10.1111/head.13552. No abstract available.

PMID:
31144299
36.

Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine.

Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK, Gaul C.

Brain. 2019 Jul 1;142(7):1894-1904. doi: 10.1093/brain/awz134.

37.

Marco Polo of Australian neurology.

Kiernan MC, Goadsby PJ, Burke D.

J Neurol Neurosurg Psychiatry. 2019 Jun;90(6):627-628. doi: 10.1136/jnnp-2019-320989. Epub 2019 May 2. No abstract available.

PMID:
31048340
38.

N-Methyl-d-aspartate receptor open-channel blockers memantine and magnesium modulate nociceptive trigeminovascular neurotransmission in rats.

Hoffmann J, Storer RJ, Park JW, Goadsby PJ.

Eur J Neurosci. 2019 Sep;50(5):2847-2859. doi: 10.1111/ejn.14423. Epub 2019 Jun 3.

PMID:
31009120
39.

Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis.

Goadsby PJ, Dodick DW, Martinez JM, Ferguson MB, Oakes TM, Zhang Q, Skljarevski V, Aurora SK.

J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):939-944. doi: 10.1136/jnnp-2018-320242. Epub 2019 Apr 19.

40.

Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study.

Goadsby PJ, Paemeleire K, Broessner G, Brandes J, Klatt J, Zhang F, Picard H, Lenz R, Mikol DD.

Cephalalgia. 2019 Jun;39(7):817-826. doi: 10.1177/0333102419835459. Epub 2019 Apr 13.

PMID:
30982348
41.

The discovery and development of inhaled therapeutics for migraine.

Vandenbussche N, Goadsby PJ.

Expert Opin Drug Discov. 2019 Jun;14(6):591-599. doi: 10.1080/17460441.2019.1598373. Epub 2019 Mar 29. Review.

PMID:
30924698
42.

Health state utilities associated with attributes of migraine preventive treatments based on patient and general population preferences.

Matza LS, Deger KA, Vo P, Maniyar F, Goadsby PJ.

Qual Life Res. 2019 Sep;28(9):2359-2372. doi: 10.1007/s11136-019-02163-3. Epub 2019 Mar 28.

43.

Author response: Gray matter volume modifications in migraine: A cross-sectional and longitudinal study.

Filippi M, Messina R, Goadsby PJ, Rocca MA.

Neurology. 2019 Mar 19;92(12):587-588. doi: 10.1212/WNL.0000000000007132. No abstract available.

PMID:
30886079
44.

Discovery of CGRP in relation to migraine.

Edvinsson L, Goadsby PJ.

Cephalalgia. 2019 Mar;39(3):331-332. doi: 10.1177/0333102418779544. No abstract available.

PMID:
30827155
45.

Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition.

Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ, Mandrekar J; International Headache Society Clinical Trials Standing Committee.

Cephalalgia. 2019 May;39(6):687-710. doi: 10.1177/0333102419828967. Epub 2019 Feb 26.

46.

Teaching NeuroImages: Greater occipital nerve injection: A cautionary tale.

Wei DY, Connor S, Goadsby PJ.

Neurology. 2019 Feb 12;92(7):e746-e747. doi: 10.1212/WNL.0000000000006929. No abstract available.

PMID:
30745452
47.

Lorcaserin Safety in Overweight or Obese Patients.

Vandenbussche N, Goadsby PJ.

N Engl J Med. 2019 Jan 3;380(1):99. doi: 10.1056/NEJMc1813971. No abstract available.

PMID:
30601744
48.

Nitroglycerine triggers triptan-responsive cranial allodynia and trigeminal neuronal hypersensitivity.

Akerman S, Karsan N, Bose P, Hoffmann JR, Holland PR, Romero-Reyes M, Goadsby PJ.

Brain. 2019 Jan 1;142(1):103-119. doi: 10.1093/brain/awy313.

49.

Cortical abnormalities in episodic migraine: A multi-center 3T MRI study.

Magon S, May A, Stankewitz A, Goadsby PJ, Schankin C, Ashina M, Amin FM, Seifert CL, Mallar Chakravarty M, Müller J, Sprenger T.

Cephalalgia. 2019 Apr;39(5):665-673. doi: 10.1177/0333102418795163. Epub 2018 Dec 10.

PMID:
30525946
50.

Biological insights from the premonitory symptoms of migraine.

Karsan N, Goadsby PJ.

Nat Rev Neurol. 2018 Dec;14(12):699-710. doi: 10.1038/s41582-018-0098-4. Review.

PMID:
30448858

Supplemental Content

Loading ...
Support Center